News | April 21, 2014

Prostate Carcinoma Is the Most Frequent Diagnosis Treated at Proton Therapy Center Czech

The center in Prague offers noninvasive, outpatient treatment with 97 percent curability

Prostate Cancer Czech Proton Therapy Center Diagnosis Treatment

April 21, 2014 — Proton Therapy Center Czech is located in the capital of the Czech Republic and has successfully entered its second year of operation. Since the beginning, it has made itself available to patients from all over the world has to date has treated patients from 18 different countries — including Great Britain, France, Belgium, Germany, Norway, Switzerland and the Russian federation. The mix of clinical indications corresponds with world trends — half of the patients treated were with prostate cancer. For them proton therapy offers a new revolutionary chance for a smooth recovery and a rapid return to their usual daily lives following treatment.

Thus far, oncology patients have undergone proton therapy with no complications and the detailed examinations given after treatment only confirm that their health improving and they have great perspectives on their future quality of life without undesirable treatment-related side effects — that are often associated with the conventional radiation methods.

Proton Therapy Center Czech in Prague utilizes the most advanced form of proton therapy scanning available today — in the form of what is simply referred to as pencil beam scanning. This remarkable tool enables tumor treatment with millimeter precision, without damaging to surrounding healthy structures. Additionally all diagnostic methods including positron emission tomography/computed tomography (PET/CT) are available in a single, centralized location. Therefore examinations and planning times are shortened by up to 14 days. It is well established fact that surgery and conventional radiotherapy using photons (X-rays), can cause serious long-term side effects such as erectile dysfunction, loss of fertility, as well as various forms of urinary incontinence, rectal inflammation and bleeding, and intestinal fibrosis. While conventional X-ray radiation unnecessarily exposes up to 50 percent more health tissue to unwanted radiation, protons on the other hand can be precisely focused only upon the tumor without damaging sensitive health organs and tissues around it. Last but not least, the majority of patients are able to maintain their sexual potency.

Ji?í Kubeš, Ph.D., Head of Proton Therapy at Proton Therapy Center Czech said, “Proton radiotherapy offers the highest chance for maintaining sexual potency after treatment. The percentage of those who suffer from incontinence is much smaller than after surgery. A very low dose of radiation decreases the risk of damage to intestines. From our treatment experience thus far, the acute complications regress 14 days following the end of treatment. This means that none of our patients were forced to limit his or her life and work activities during treatment. Patients have not needed to go on sick leave at all during their treatment.“

The excellent results of treatment of prostate can be demonstrated by the new report from Washington by National Association for Proton Therapy.

For more information:

Related Content

SpaceOAR Hydrogel Now Available in Japan
News | Patient Positioning Radiation Therapy | July 16, 2018
Augmenix K.K. announced that SpaceOAR hydrogel, a soft, implanted absorbable gel spacer is now available to all...
RaySearch Releases New Version of RayCare OIS
Technology | Oncology Information Management Systems (OIMS) | July 13, 2018
RaySearch has released RayCare 2A, the latest version of its flagship oncology information system (OIS). RayCare is...
Lack of Insurance Coverage Delaying Proton Therapy Clinical Trials
News | Proton Therapy | July 12, 2018
Randomized clinical trials are the gold standard of cancer research and can shed light on whether innovative, new...
Bruce Power Joins Forces With ITM to Supply Lutetium-177 for Cancer Therapy
News | Radiation Therapy | July 11, 2018
Canadian nuclear power company Bruce Power and German-based Isotope Technologies Garching (ITG) signed an agreement to...
MedStar Georgetown University Hospital Now Clinical With RayStation and Hyperscan
News | Treatment Planning | July 05, 2018
MedStar Georgetown University Hospital in Washington D.C., has begun patient treatments using the RayStation treatment...
Northern Centre for Cancer Care (NCCC)

Northern Centre for Cancer Care (NCCC).

Sponsored Content | Case Study | Radiation Therapy | July 05, 2018
Established in 2009, Northern Centre for Cancer Care (NCCC) is the largest center of its kind in the north of England....
Feature | Proton Therapy | July 03, 2018 | By Jeff Zagoudis
The Alliance for Proton Therapy Access (APTA) released a national report in late May revealing the heavy emotional and...
Researcher Investigates Eliminating Radiation for HER2-Positive Breast Cancer
News | Radiation Therapy | July 02, 2018
Researchers at The University of Kansas Cancer Center have launched a clinical trial that eliminates radiation from the...
SNMMI Image of the Year Highlights Theranostic Approach for Advanced Prostate Cancer

IMAGE OF THE YEAR: PSMA PET before and after lutetium-177 PSMA617 theranostics in 8 patients with metastatic prostate cancer who exhausted standard therapeutic options.

68Ga-PSMA11 PET maximum intensity projection (MIP) images at baseline and 3 months after 177Lu-PSMA617 in 8 patients with PSA decline ≥ 98 percent in a prospective phase II study. Any disease with SUV over 3 is in red. Credit: Michael Hofman, John Violet, Shahneen Sandhu, Justin Ferdinandus, Amir Iravani, Grace Kong, Aravind Ravi Kumar, Tim Akhurst, Sue Ping Thang, Price Jackson, Mark Scalzo, Scott Williams and Rodney Hicks, Peter MacCallum Cancer Centre, Melbourne, Australia.

News | PET Imaging | June 29, 2018
In the battle against metastatic castrate-resistant prostate cancer, studies have demonstrated a high response rate to...
Technology | Focused Ultrasound Therapy | June 19, 2018
EDAP TMS SA has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Focal One device for...
Overlay Init